Recommendation guideline of Korean Society of Gynecologic Oncology and Colposcopy for quadrivalent human papillomavirus vaccine.
- Author:
Byoung Gie KIM
1
;
Nak Woo LEE
;
Seung Cheol KIM
;
Young Tae KIM
;
Yong Man KIM
;
Chan Joo KIM
;
Sang Yoon PARK
;
Yong Sang SONG
;
Jae Kwan LEE
;
Won Chul LEE
;
Nam Hoon CHO
;
Chi Hum CHO
;
Soo Young HUR
;
Jong Sup PARK
;
Kyu Wan LEE
Author Information
1. Department of Obstetrics and Gynecology, Sungkyunkwan University School of Medicine.
- Publication Type:Review ; Clinical Trial
- Keywords:
HPV;
cervical cancer;
genital wart;
HPV vaccine
- MeSH:
Aluminum;
Capsid Proteins;
Colposcopy*;
Condylomata Acuminata;
DNA, Recombinant;
Female;
Human papillomavirus 6;
Humans*;
Korea;
Mass Screening;
Uterine Cervical Neoplasms;
Vaccination;
Virion;
Vulvar Neoplasms;
Yeasts
- From:Korean Journal of Gynecologic Oncology
2007;18(4):259-283
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Genital HPV infection is the most common sexually transmitted infection, but the majority of infections are self-limited. However, persistent infection with high-risk types can cause cervical cancer in women, which is the most common female genital cancer in Korea. In addition, HPV infection is the cause of genital warts and is associated with other anogenital cancers. The HPV vaccine is composed of the HPV L1 protein, the major capsid protein of HPV. Expression of the L1 protein in yeast using recombinant DNA technology produces noninfectious virus-like particles (VLP) that resemble HPV virions. The quadrivalent HPV vaccine is a mixture of four HPV type-specific VLPs prepared from the L1 proteins of HPV 6, 11, 16, and 18 combined with an aluminum adjuvant. Clinical trials indicate that the vaccine has high efficacy in preventing persistent HPV infection, cervical cancer precursor lesions, vaginal and vulvar cancer precursor lesions, and genital warts caused by HPV types 6, 11, 16, or 18 among females who have not already been infected with the respective HPV type. The recommended age for primary vaccination of Korean females is 15-17 years, considering sexual debut and duration of protection of the vaccine. Vaccine can be administered as young as age 9 years. Catch-up vaccination is recommended for females aged 18-26 years who have not been previously vaccinated. Vaccination is not a substitute for routine cervical cancer screening, and vaccinated females should have cervical cancer screening as recommended.
